Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Irhythm Holdings Inc's Business Segments
Irhythm Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
4
Largest Segment
Commercial Payors
Total Revenue
$ 224
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Commercial Payors98.4%
- Centers for Medicare & Medicaid Services49%
- Healthcare institutions30.3%
- Non-contracted third-party payors11.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Commercial Payors | $ 221 | 98.4% |
| Centers for Medicare & Medicaid Services | $ 110 | 49% |
| Healthcare institutions | $ 68 | 30.3% |
1 more segments available
Sign in to unlock the full Irhythm Holdings Inc dataset.
Revenue by Product & Service Category - FY
- Commercial Payors53.6%
- Centers for Medicare & Medicaid Services25.8%
- Healthcare institutions15.1%
- Non-contracted third-party payors5.5%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Commercial Payors | $ 107 | 53.6% |
| Centers for Medicare & Medicaid Services | $ 51 | 25.8% |
| Healthcare institutions | $ 30 | 15.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Irhythm Holdings Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Commercial Payors98.4%
- Centers for Medicare & Medicaid Services49%
- Healthcare institutions30.3%
- Non-contracted third-party payors11.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Commercial Payors | $ 221 | 98.4% |
| Centers for Medicare & Medicaid Services | $ 110 | 49% |
| Healthcare institutions | $ 68 | 30.3% |
1 more segments available
Sign in to unlock the full Irhythm Holdings Inc dataset.
Description of Irhythm Holdings Inc
iRhythm Technologies Inc, founded in 2006, is a healthcare technology company that provides remote cardiac monitoring solutions. The company offers two key product lines: Zio XT and IQVIA. These products help physicians diagnose patients with heart arrhythmias and monitor their heart activity outside of the hospital.
Zio XT is a continuous wearable cardiac monitor that patients wear for up to 14 days. It allows physicians to collect more data than traditional Holter monitors - which can only be worn for 24-48 hours. The device can be worn during normal daily activities, including showering and sleeping, and it provides continuous ECG recordings which can be accessed remotely by physicians. These recordings help doctors diagnose cardiac arrhythmias.
IQVIA, on the other hand, is an AI-powered platform that uses machine learning algorithms to analyze large amounts of patient data to identify potential cardiac arrhythmias. It can use data from various sources such as EHRs, mobile devices, and wearables such as the Zio XT. The platform enables healthcare practitioners to personalize treatment for patients based on their individual needs and risk factors.
The company's products have received FDA clearance and are recognized as one of the most advanced cardiac monitoring technologies available. They have also been featured in several clinical studies, including a trial that demonstrated the effectiveness of Zio XT in diagnosing atrial fibrillation.
iRhythm Technologies Inc's headquarters are in San Francisco, California, but they also have additional offices in Minnesota, North Carolina, and internationally in Germany and the UK. The company is listed on NASDAQ with ticker symbol "IRTC". They continue to expand their product offerings and partnerships with other healthcare providers to improve patient outcomes and reduce unnecessary hospital visits.
Zio XT is a continuous wearable cardiac monitor that patients wear for up to 14 days. It allows physicians to collect more data than traditional Holter monitors - which can only be worn for 24-48 hours. The device can be worn during normal daily activities, including showering and sleeping, and it provides continuous ECG recordings which can be accessed remotely by physicians. These recordings help doctors diagnose cardiac arrhythmias.
IQVIA, on the other hand, is an AI-powered platform that uses machine learning algorithms to analyze large amounts of patient data to identify potential cardiac arrhythmias. It can use data from various sources such as EHRs, mobile devices, and wearables such as the Zio XT. The platform enables healthcare practitioners to personalize treatment for patients based on their individual needs and risk factors.
The company's products have received FDA clearance and are recognized as one of the most advanced cardiac monitoring technologies available. They have also been featured in several clinical studies, including a trial that demonstrated the effectiveness of Zio XT in diagnosing atrial fibrillation.
iRhythm Technologies Inc's headquarters are in San Francisco, California, but they also have additional offices in Minnesota, North Carolina, and internationally in Germany and the UK. The company is listed on NASDAQ with ticker symbol "IRTC". They continue to expand their product offerings and partnerships with other healthcare providers to improve patient outcomes and reduce unnecessary hospital visits.
iRhythm Technologies Inc. is at the forefront of healthcare technology, particularly in the realm of cardiac care, focusing on the development of advanced monitoring solutions for patients experiencing cardiac arrhythmias. Established in 2006 and based in San Francisco, California, the company aims to enhance the identification, diagnosis, and management of heart conditions through innovative products and services.
Segments
iRhythm Technologies operates in two principal segments:
1. Diagnosis and Monitoring Services
2. Data and Analytics Services
1. Diagnosis and Monitoring Services
The cornerstone of iRhythms offerings is its wearable diagnostic monitoring technology. The flagship product, the ZioXT Patch, allows continuous heart rhythm monitoring.
- ZioXT Patch:
- This device can record a patient’s heart rhythm for up to two weeks, providing an extensive window for monitoring. It is designed to be small, lightweight, and water-resistant, which enables patients to carry on with their daily activities without interruption.
- The ZioXT Patch employs advanced algorithms to detect and characterize various cardiac arrhythmias, such as atrial fibrillation (AFib), bradycardia, and tachycardia. Its design allows it to be worn discreetly under clothing, making it a convenient option for patients.
This segment aims to empower cardiologists by providing them with concrete data that aids in diagnosing and monitoring patients afflicted with cardiac issues.
Data and Analytics Services
In tandem with its diagnostic devices, iRhythm Technologies delivers robust data and analytics services, which augment the effectiveness of its monitoring solutions.
- iRhythm Care Platform:
- This comprehensive platform aggregates the data collected from the ZioXT Patch, employing state-of-the-art artificial intelligence (AI) and machine learning algorithms for real-time analysis.
- The platform identifies abnormal heart rhythms and generates alerts for physicians, facilitating prompt responses to potential health issues.
- Additionally, the platform can integrate seamlessly with electronic health records (EHRs) and other clinical systems, offering a cohesive approach to patient data management.
Products
The primary products offered by iRhythm Technologies include:
1. ZioXT Patch
- A revolutionary device that monitors heart rhythm using sophisticated technology. It offers a two-week monitoring duration, waterproof design, and advanced detection capabilities.
2. iRhythm Care Platform
- A sophisticated analytics platform that processes and analyzes heart rhythm data from the ZioXT Patch. Its equipped to provide actionable insights to healthcare providers, enhancing diagnostic accuracy and patient management.
Services
iRhythm Technologies also offers a variety of services that support healthcare professionals, patients, and payers:
1. Diagnosis and Monitoring Services
- Through the ZioXT Patch, the company extends tools that allow for accurate diagnosis and ongoing monitoring of cardiac patients, sharing the responsibility of care with healthcare providers.
2. Data and Analytics Services
- With the iRhythm Care Platform, iRhythm empowers physicians by transforming complex data into understandable insights, thus streamlining the decision-making process in patient treatment plans.
3. Patient and Payer Support Services
- iRhythm provides extensive support for both patients and payers, aimed at enhancing outcomes and managing healthcare costs. Services may include patient education, personalized guidance on monitoring, and assistance with reimbursement processes to facilitate access to healthcare resources.
Conclusion
iRhythm Technologies Inc. stands as a pivotal player in the healthcare landscape, particularly within cardiac care. The companys innovative products and services are not only designed to enhance patient outcomes but also to reduce costs and improve overall efficiency in the diagnosis and management of cardiac arrhythmias. Through the integration of advanced monitoring technology and cutting-edge analytics, iRhythm is redefining the approach to cardiac health, paving the way for improved healthcare delivery and patient experiences.
Segments
iRhythm Technologies operates in two principal segments:
1. Diagnosis and Monitoring Services
2. Data and Analytics Services
1. Diagnosis and Monitoring Services
The cornerstone of iRhythms offerings is its wearable diagnostic monitoring technology. The flagship product, the ZioXT Patch, allows continuous heart rhythm monitoring.
- ZioXT Patch:
- This device can record a patient’s heart rhythm for up to two weeks, providing an extensive window for monitoring. It is designed to be small, lightweight, and water-resistant, which enables patients to carry on with their daily activities without interruption.
- The ZioXT Patch employs advanced algorithms to detect and characterize various cardiac arrhythmias, such as atrial fibrillation (AFib), bradycardia, and tachycardia. Its design allows it to be worn discreetly under clothing, making it a convenient option for patients.
This segment aims to empower cardiologists by providing them with concrete data that aids in diagnosing and monitoring patients afflicted with cardiac issues.
Data and Analytics Services
In tandem with its diagnostic devices, iRhythm Technologies delivers robust data and analytics services, which augment the effectiveness of its monitoring solutions.
- iRhythm Care Platform:
- This comprehensive platform aggregates the data collected from the ZioXT Patch, employing state-of-the-art artificial intelligence (AI) and machine learning algorithms for real-time analysis.
- The platform identifies abnormal heart rhythms and generates alerts for physicians, facilitating prompt responses to potential health issues.
- Additionally, the platform can integrate seamlessly with electronic health records (EHRs) and other clinical systems, offering a cohesive approach to patient data management.
Products
The primary products offered by iRhythm Technologies include:
1. ZioXT Patch
- A revolutionary device that monitors heart rhythm using sophisticated technology. It offers a two-week monitoring duration, waterproof design, and advanced detection capabilities.
2. iRhythm Care Platform
- A sophisticated analytics platform that processes and analyzes heart rhythm data from the ZioXT Patch. Its equipped to provide actionable insights to healthcare providers, enhancing diagnostic accuracy and patient management.
Services
iRhythm Technologies also offers a variety of services that support healthcare professionals, patients, and payers:
1. Diagnosis and Monitoring Services
- Through the ZioXT Patch, the company extends tools that allow for accurate diagnosis and ongoing monitoring of cardiac patients, sharing the responsibility of care with healthcare providers.
2. Data and Analytics Services
- With the iRhythm Care Platform, iRhythm empowers physicians by transforming complex data into understandable insights, thus streamlining the decision-making process in patient treatment plans.
3. Patient and Payer Support Services
- iRhythm provides extensive support for both patients and payers, aimed at enhancing outcomes and managing healthcare costs. Services may include patient education, personalized guidance on monitoring, and assistance with reimbursement processes to facilitate access to healthcare resources.
Conclusion
iRhythm Technologies Inc. stands as a pivotal player in the healthcare landscape, particularly within cardiac care. The companys innovative products and services are not only designed to enhance patient outcomes but also to reduce costs and improve overall efficiency in the diagnosis and management of cardiac arrhythmias. Through the integration of advanced monitoring technology and cutting-edge analytics, iRhythm is redefining the approach to cardiac health, paving the way for improved healthcare delivery and patient experiences.